raloxifene hydrochloride has been researched along with Recrudescence in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
Authors | Studies |
---|---|
Azami, N; Chen, PJ; Dutra, EH; Kalajzic, Z; Mehta, S; Nanda, R; Yadav, S | 1 |
Bauer, DC; Clarke, BL; Drake, MT; Tsourdi, E; Yu, EW | 1 |
Chiodini, A; Odorizzi, MP; Pompei, F; Somigliana, E; ViganĂ², P | 1 |
Adachi, JD; Crans, GG; Delmas, PD; Genant, HK; Siris, E; Stock, JL; Wong, M | 1 |
Deng, W; He, W | 1 |
Leondires, M; Nieman, LK; Parker, JD; Premkumar, A; Sinaii, N; Stratton, P | 1 |
Koziol, D; Nieman, LK; Segars, J; Sinaii, N; Stratton, P; Wesley, R; Winkel, C; Zimmer, C | 1 |
Adachi, JD; Harper, KD; Maricic, M; Sarkar, S; Wong, M; Wu, W | 1 |
1 review(s) available for raloxifene hydrochloride and Recrudescence
Article | Year |
---|---|
[The therapy of endometriosis. New prospects].
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents; Aromatase Inhibitors; Clinical Trials as Topic; Drug Evaluation, Preclinical; Endometriosis; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Hypothalamo-Hypophyseal System; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Papio; Pregnancy; Pregnancy Rate; Raloxifene Hydrochloride; Rats; Recurrence; Selective Estrogen Receptor Modulators; Tissue Adhesions | 2003 |
4 trial(s) available for raloxifene hydrochloride and Recrudescence
Article | Year |
---|---|
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.
Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk Factors; Spinal Fractures | 2003 |
Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis.
Topics: Adult; Dysmenorrhea; Endometriosis; Female; Humans; Laparoscopy; Pelvic Pain; Raloxifene Hydrochloride; Recurrence; Selective Estrogen Receptor Modulators; Severity of Illness Index; Treatment Failure; Treatment Outcome | 2006 |
Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial.
Topics: Adult; Chronic Disease; Endometriosis; Female; Humans; Laparoscopy; Pelvic Pain; Quality of Life; Raloxifene Hydrochloride; Recurrence; Selective Estrogen Receptor Modulators; Treatment Outcome | 2008 |
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors | 2002 |
3 other study(ies) available for raloxifene hydrochloride and Recrudescence
Article | Year |
---|---|
Raloxifene administration enhances retention in an orthodontic relapse model.
Topics: Animals; Bone Remodeling; Male; Molar; Osteoclasts; Raloxifene Hydrochloride; Rats; Rats, Wistar; Recurrence; Tooth Movement Techniques | 2020 |
Osteoporosis Management in the Era of COVID-19.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Continuity of Patient Care; Coronavirus Infections; COVID-19; Denosumab; Disease Management; Drug Administration Schedule; Estrogen Replacement Therapy; Fractures, Spontaneous; Home Care Services; Humans; Immunosuppression Therapy; Osteoporosis; Pandemics; Pneumonia, Viral; Raloxifene Hydrochloride; Recurrence; Telemedicine; Thrombophilia; Unnecessary Procedures | 2020 |
Identifying methodologies in the assessment of treatment effects on the repeated occurrences of hot flashes in postmenopausal women.
Topics: Analysis of Variance; Clinical Trials as Topic; Computer Simulation; Female; Hot Flashes; Humans; Logistic Models; Markov Chains; Models, Statistical; Raloxifene Hydrochloride; Recurrence; Research Design; Selective Estrogen Receptor Modulators; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |